Glucon, Suzuken in glucose monitoring device deal
This article was originally published in Clinica
Boulder, Colorado-based Glucon has struck a deal with Japanese pharmaceuticals distributor Suzuken concerning the former's glucose monitoring watch (GMW). Under the agreement, Suzuken, which controls 50% of the Japanese diabetes market through its SKK subsidiary, will gain exclusive marketing rights to GMW in that region and be responsible for taking the product through the Japanese regulatory process. In exchange, Suzuken has made an equity investment in Glucon during a recent round of financing, in which other venture capital firms including Giza Venture Capital, Infinity Venture Capital Fund, Reslo Life Sciences and Ascend Technology Ventures also took part.